Literature DB >> 11812737

Interleukin-1 plus gamma-interferon-induced pancreatic beta-cell dysfunction is mediated by beta-cell nitric oxide production.

Helen E Thomas1, Rima Darwiche, John A Corbett, Thomas W H Kay.   

Abstract

Cytokines have been implicated in pancreatic beta-cell destruction leading to type 1 diabetes. In vitro, a combination of gamma-interferon (IFN-gamma) and interleukin-1 (IL-1) stimulate inducible nitric oxide synthase (iNOS) expression in islets, and the resulting increased production of nitric oxide (NO) causes islet cell destruction. Islets contain macrophages, ductal cells, and endothelial cells that, when activated, may mediate islet cell damage by producing either NO themselves or cytokines that then stimulate NO production by beta-cells. The aim of this study was to determine whether beta-cell damage mediated by cytokine-induced NO production is dependent on beta-cell production of NO, or whether NO produced by other cells in the islet is capable of destroying beta-cells. To address this aim, we used transgenic mice expressing a dominant-negative IFN-gamma receptor in beta-cells (RIP-Delta(gamma)R). RIP-Delta(gamma)R islets are resistant to IL-1 + IFN-gamma-induced inhibition of insulin secretion and DNA damage, indicating that beta-cell IFN-gamma responsiveness is required for IL-1 + IFN-gamma-mediated beta-cell damage. Although islets isolated from RIP-Delta(gamma)R mice are resistant to functional damage, these islets produce NO in response to IL-1 + IFN-gamma, but at a lower concentration than that produced by wild-type islets. beta-Cells appear to be the primary cellular source of IL-1 + IFN-gamma-induced iNOS expression in wild-type islets. In contrast, IL-1 + IFN-gamma fail to stimulate iNOS expression by insulin-expressing cells in islets isolated from RIP-DeltagammaR mice. IL-1 + IFN-gamma-induced expression of iNOS was detected in non-beta-cells in both wild-type and RIP-DeltagammaR islets. These findings support the hypothesis that NO must be produced by beta-cells to induce damage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11812737     DOI: 10.2337/diabetes.51.2.311

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  52 in total

Review 1.  Effector lymphocytes in islet cell autoimmunity.

Authors:  Pere Santamaria
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 2.  Viruses and cytotoxic T lymphocytes in type 1 diabetes.

Authors:  Ken T Coppieters; Matthias G von Herrath
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

Review 3.  Challenges and emerging technologies in the immunoisolation of cells and tissues.

Authors:  John T Wilson; Elliot L Chaikof
Journal:  Adv Drug Deliv Rev       Date:  2007-10-11       Impact factor: 15.470

Review 4.  Small G proteins in islet beta-cell function.

Authors:  Anjaneyulu Kowluru
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

Review 5.  Epigenetics: the missing link to understanding β-cell dysfunction in the pathogenesis of type 2 diabetes.

Authors:  Elizabeth R Gilbert; Dongmin Liu
Journal:  Epigenetics       Date:  2012-07-19       Impact factor: 4.528

6.  Regulation of iNOS gene transcription by IL-1β and IFN-γ requires a coactivator exchange mechanism.

Authors:  Susan J Burke; Barrett L Updegraff; Rachel M Bellich; Matthew R Goff; Danhong Lu; Steven C Minkin; Michael D Karlstad; J Jason Collier
Journal:  Mol Endocrinol       Date:  2013-09-06

7.  Severe pancreatitis with exocrine destruction and increased islet neogenesis in mice with suppressor of cytokine signaling-1 deficiency.

Authors:  Ye Chen; Mark M W Chong; Rima Darwiche; Helen E Thomas; Thomas W H Kay
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

8.  CD40 expression on human pancreatic duct cells: role in nuclear factor-kappa B activation and production of pro-inflammatory cytokines.

Authors:  O Vosters; C Beuneu; N Nagy; B Movahedi; E Aksoy; I Salmon; D Pipeleers; M Goldman; V Verhasselt
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

Review 9.  Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices.

Authors:  Shang Song; Shuvo Roy
Journal:  Biotechnol Bioeng       Date:  2016-01-04       Impact factor: 4.530

10.  Thrombosis and inflammation in intraportal islet transplantation: a review of pathophysiology and emerging therapeutics.

Authors:  John T Wilson; Elliot L Chaikof
Journal:  J Diabetes Sci Technol       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.